322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
The Readout Loud
00:00
Intro
This chapter explores groundbreaking developments in cancer immunotherapy, focusing on a new drug that has shown better results than Merck's Keytruda in lung cancer trials. It also covers significant biotech updates, including Moderna's budget cuts and emerging obesity treatments for children, while highlighting the influence of key figures in cancer treatment advancements.
Transcript
Play full episode
